Program
reproxalap
Also written as “Reproxalap Ophthalmic Solution (0.25%)”, “Reproxalap Ophthalmic Solution (0.5%)” and “ADX-102 Ophthalmic Solution (0.5%)”.
Its studies are mostly in Dry Eye Syndromes · Conjunctivitis, Allergic · Alopecia Areata · Uveitis, Anterior, led by 2 companies.
Drug pageReproxalap: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Aldeyra Therapeuticsits history only | 200 open or running | phase 3since Apr 4, 2017 | Dec 14, 2016 | none ahead |
| Aldena Therapeutics | 11 open or running | phase 2since Jan 22, 2025 | Jan 22, 2025 | Nov 2026phase 2 · NCT06826196 |
Also a collaborator on its studies: ORA.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Aldena Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2018Named reproxalapINNProposed as its International Nonproprietary Name in WHO's List 119
- Jan 22, 2025First study: phase 2 study in Alopecia AreataFirst studyNCT06826196 · 9 enrolled · United States, Canada
Ahead
- Nov 2026Primary completion: phase 2 study in Alopecia AreataNCT06826196
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Aldena Therapeutics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06826196Alopecia Areata · United States, Canada | 2 | Active, not recruiting | Nov 2026 | 9 |
How it is read
Names in the registry
- “Reproxalap Ophthalmic Solution (0.25%)”, 15 entries
- “Reproxalap Ophthalmic Solution (0.5%)”, 3 entries
- “ADX-102 Ophthalmic Solution (0.5%)”, 2 entries
- “ALD-102 Solution”, 1 entry
- “Reproxalap ophthalmic solution (0.25%)”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 12 studies
- Conjunctivitis, Allergic, 6 studies
- Alopecia Areata, 1 study
- Uveitis, Anterior, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.